Marker Therapeutics (FRA:GX1) Forward Dividend Yield % : 0.00% (As of May. 28, 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Forward Dividend Yield %?

As of today (2024-05-28), the Forward Annual Dividend Yield of Marker Therapeutics is 0.00%.

As of today (2024-05-28), the Trailing Annual Dividend Yield of Marker Therapeutics is 0.00%.

FRA:GX1's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

Marker Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Marker Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Marker Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Forward Dividend Yield % falls into.

Marker Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Marker Therapeutics (FRA:GX1) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Marker Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (FRA:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines